Co-led by Legend Capital, Huili Biotechnology Completes Series A Financing Round with Hundreds of Million RMB
2022年7月7日 - 8:16PM
JCN Newswire
Jiangsu Huili Biotechnology Co., Ltd ("Huili Bio"), a
next-generation synthetic biology enzyme computational design
platform, recently announced the completion of its Series A
financing round with hundreds of million RMB. This financing round
was co-led by Legend Capital and the fresh capital will be used to
accelerate the construction and operation of large-scale production
facilities, the R&D of new product pipelines and the expansion
of the talent team.
Founded in 2018, Huili Bio is dedicated to the computational design
of enzyme components at the core of synthetic biological reactions.
With cutting-edge achievements, Huili Bio is one of the few
bio-manufacturing companies with comprehensive capabilities in core
technology, mass production on a large scale and closed-loop
commercialization. It provides solutions in multiple fields such as
pharmaceutical intermediates, animal protection and food. In
addition to an R&D center in Tianjin, Huili Bio has also
established a production base in Taizhou City, Jiangsu Province,
which is under the expansion of flexible production line.
Huili Bio's enzyme computational design platform is the first
computational platform in China to realize the full-scenario design
of enzymes. This platform enables the company to transform products
in the pharmaceutical field, so as to achieve high efficiency from
laboratory development, industrial production to commercialization,
reducing costs by nearly 30% and increasing yields by almost 70%
compared to traditional chemical methods, and also helps Huili Bio
deploy more than 10 innovative products in various fields.
Commenting on the financing, Henry JI, Executive Director of Legend
Capital, said: "The synthetic biomaterials market is vast and an
important area in the green and low-carbon direction. As the core
component of synthetic biology, the design and transformation of
enzymes will benefit more traditional biotechnology industries with
low-cost and sustainable green production methods. Legend Capital
has long focused on investment in the 'IT+' industry, and Huili Bio
is a model of combining information technology and biotechnology
(IT+BT). With a background in combining industry and research,
Huili Bio is a company with differentiated product selection and
multi-pipeline extension capabilities. The company has mastered the
industry's leading enzyme computing design technology and has
rapidly achieved the scale production of high-value-added products
such as pharmaceutical intermediates through the layout of the
whole industry chain and has been fully recognized by the
industry's head customers. Legend Capital is glad to join hands
with Huili Biotech to contribute to China's biological
'intelligence'."
As an intersection of information science, life science and
material science, synthetic biology and bio-based materials have
been the focus of Legend Capital's carbon-neutral technology
investments. Under the background of carbon peaking and carbon
neutrality, Legend Capital's investments focus on energy
decarbonization, vehicle electrification/intelligence, synthetic
biology, etc. Energy decarbonization includes photovoltaic, wind
power and smart grid; vehicle electrification/intelligence includes
lithium battery vehicles, hydrogen fuel cell vehicles, battery
recycling and others. Legend Capital has made investments in the
field of synthetic biology by investing in outstanding companies
such as Huili Bio, Zhongke Guosheng, and Tidetron Bio.
About Legend Capital
Founded in 2001, Legend Capital is a leading VC&PE investor
focusing on the early-stage and growth-stage opportunities in
China, with offices across Beijing, Shanghai, Shenzhen, Hong Kong,
and Seoul, South Korea.
It currently manages USD and RMB funds of over US$10 billion in
commitments, and has invested in around 600 companies, covering
technology, healthcare, consumer, enterprise service and
intelligent manufacturing sectors. Rooted in China, Legend Capital
participated in the rise of many world-leading companies by solid
investment coverage and systematic post-investment value-add. Over
the years, Legend Capital has also become a widely recognized name
in bridging key resources in China and overseas through
cross-border activities, and a valuable partner to Chinese and
overseas investors.
Legend Capital values long-term sustainable investment and
incorporates ESG into its long-term development strategy. As a
UNPRI signatory since November 2019, Legend Capital is among the
first group of top VC/PE firms in China to join the initiative.
For more information, please visit
www.legendcapital.com.cn/index_en.aspx and follow us on LinkedIn
@Legend Capital ( https://www.linkedin.com/company/legend-capital
).
Copyright 2022 JCN Newswire . All rights reserved.